[Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia]. / Confronto dell'efficacia di pantetina, acipimox e bezafibrato sui lipidi plasmatici ed indice di rischio cardiovascolare in diabetici dislipidemici.
Minerva Med
; 82(10): 657-63, 1991 Oct.
Article
en It
| MEDLINE
| ID: mdl-1745376
ABSTRACT
Atherosclerotic manifestations are more common and precocious in diabetics than in the general population. Due to the increased cardiovascular risk, a primary or secondary (to diabetes mellitus) lipoprotein disorder in diabetics has to be carefully considered. 27 diabetics (15 NIDDM and 12 IDDM) with dyslipidemia (14 type IV, 8 type IIa and 5 type IIb) were divided in 3 groups and treated with 3 different hypolipemic drugs (Group A pantethine 600 mg/day; Group B acipimox 500 mg/day; Group C bezafibrate 600 mg/day) to test their efficacy and acceptancy. Body weight, Hb A1-c, serum lipoproteins have been measured before and during the 6 months treatment. A significant variation of lipidemic pattern was observed in Group C a decrease of cholesterol (-20%), triglycerides (-40%), LDL (-24.4%) and apo B (-26.8%) with an increase of HDL (+23.6%). Pantethine and acipimox were more effective on triglycerides (-37.7% and -23.3% respectively). Cardiovascular risk (CT tot/CT HDL) was significantly reduced with acipimox and normalized with bezafibrate.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Panteteína
/
Pirazinas
/
Bezafibrato
/
Complicaciones de la Diabetes
/
Hiperlipidemias
/
Hipolipemiantes
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
It
Revista:
Minerva Med
Año:
1991
Tipo del documento:
Article